Effectiveness of Abrocitinib in Adolescent Alopecia Areata: A Prospective Observational Pilot Study

This prospective observational pilot study evaluated the effectiveness and safety of abrocitinib in 7 adolescents with moderate-to-severe alopecia areata (AA). Participants, aged 12-17, received treatment for at least 10 months. Results showed significant improvement, with 100% achieving a SALT score reduction by week 36, and 85.7% maintaining this response at the final visit. Initial hair regrowth was observed after an average of 7.7 weeks. The treatment was well-tolerated, with no serious safety concerns, although one patient experienced mild transient bilirubin elevation. The study concludes that abrocitinib is effective and tolerable, but further research is needed to establish long-term outcomes and safety in this age group.